Ovarian cancer (relapsed) - trabectedin (TA222)
Specific, concise statements that act as markers of high-quality, cost-effective patient care
NICE does not recommend trabectedin taken with PLDH (which is short for pegylated liposomal doxorubicin hydrochloride) for women with relapsed platinum-sensitive ovarian cancer.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. The evidence provided did not show that trabectedin provides more benefit than the standard treatments currently used by people with relapsed platinum-sensitive ovarian cancer in the NHS, and it costs more, so NICE did not recommend it.
- None found
This page was last updated: 08 May 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA222 Trabectedin ar gyfer canser ofar´aidd ail-wael: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.